Affinity Asset Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Affinity Asset Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-200,000	Closed	-$3.51M	–	84
2021 Q3	$3.51M	Buy	+200,000	New	+$2.34M	0.89%	28

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Affinity Asset Advisors's TRIL Position: Q4 2021 in Review

Affinity Asset Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 200,000 shares — an estimated $3.51M sold.

Affinity Asset Advisors first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $3.51M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Affinity Asset Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Affinity Asset Advisors sold 200,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $3.51M.
Affinity Asset Advisors first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Affinity Asset Advisors's Trillium Therapeutics Inc. position peaked at $3.51M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.